CN114981288A - 一种抗体结合的特征性表位及其应用 - Google Patents
一种抗体结合的特征性表位及其应用 Download PDFInfo
- Publication number
- CN114981288A CN114981288A CN202080094292.3A CN202080094292A CN114981288A CN 114981288 A CN114981288 A CN 114981288A CN 202080094292 A CN202080094292 A CN 202080094292A CN 114981288 A CN114981288 A CN 114981288A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- polypeptide fragment
- pcsk9
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 62
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 53
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 2
- 229940126582 mRNA vaccine Drugs 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 description 30
- 230000027455 binding Effects 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 102000053786 human PCSK9 Human genes 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 229940125644 antibody drug Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229960002027 evolocumab Drugs 0.000 description 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940028952 praluent Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102000000853 LDL receptors Human genes 0.000 description 4
- 108010001831 LDL receptors Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 101150094724 PCSK9 gene Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229940017164 repatha Drugs 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- URFCJEUYXNAHFI-CYBMUJFWSA-N (2r)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-CYBMUJFWSA-N 0.000 description 1
- IUNJCFABHJZSKB-UHFFFAOYSA-N 2,4-Dihydroxybenzaldehyde Natural products OC1=CC=C(C=O)C(O)=C1 IUNJCFABHJZSKB-UHFFFAOYSA-N 0.000 description 1
- DYFIKPYMDZVONX-UHFFFAOYSA-N 4-amino-n-(6-methyl-4-oxo-1h-pyrimidin-2-yl)benzenesulfonamide Chemical compound N1C(C)=CC(=O)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 DYFIKPYMDZVONX-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 231100000483 muscle toxicity Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
提供一种多肽片段及其制备方法,所述多肽片段包含从N端至C端如X1X 2X 3X 4X 5GX 6所示的氨基酸序列,其中,X1为S、T、E、Y或F;X2为T、N、G、S或D;X3为H、E、Y、T、K、R或A;X4为G、Y、H、R或M;X5为A、F、Q、H、I或V;X6为W或F。还公开了编码该多肽的分离的核酸分子,并利用该多肽来制作针对PCSK9的多肽疫苗。该多肽片段可与抗PCSK9抗体结合,可检测、筛选或辅助筛选新的抗PCSK9抗体,从而缓解患者对原抗体出现免疫原性强等不良反应的问题。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/104876 WO2022021000A1 (zh) | 2020-07-27 | 2020-07-27 | 一种抗体结合的特征性表位及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114981288A true CN114981288A (zh) | 2022-08-30 |
CN114981288B CN114981288B (zh) | 2024-05-03 |
Family
ID=80037278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080094292.3A Active CN114981288B (zh) | 2020-07-27 | 2020-07-27 | 一种抗体结合的特征性表位及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114981288B (zh) |
WO (1) | WO2022021000A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
CN102206249A (zh) * | 2011-04-26 | 2011-10-05 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒ns1蛋白特异性b细胞抗原表位多肽及其应用 |
CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
CN105085684A (zh) * | 2014-05-14 | 2015-11-25 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
CN108883166A (zh) * | 2016-03-25 | 2018-11-23 | 国立大学法人大阪大学 | 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗 |
CN109475593A (zh) * | 2016-06-24 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于治疗心血管疾病的组合物和方法 |
CN109897110A (zh) * | 2017-12-08 | 2019-06-18 | 深圳华大生命科学研究院 | 纳米抗体及其制备方法 |
CN110072876A (zh) * | 2016-12-09 | 2019-07-30 | 深圳华大生命科学研究院 | 多肽及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673850B2 (en) * | 2008-05-30 | 2014-03-18 | Institut De Recherches Cliniques De Montreal | PCSK9 inhibitors and methods of use thereof |
WO2011037791A1 (en) * | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
CN110042066A (zh) * | 2010-12-01 | 2019-07-23 | 默沙东公司 | 表面锚定的fc-诱饵抗体展示系统 |
AU2014230460B2 (en) * | 2013-03-14 | 2018-04-05 | Pieris Pharmaceuticals Gmbh | Novel binding proteins for PCSK9 |
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
CN107474140B (zh) * | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
-
2020
- 2020-07-27 WO PCT/CN2020/104876 patent/WO2022021000A1/zh active Application Filing
- 2020-07-27 CN CN202080094292.3A patent/CN114981288B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
CN102206249A (zh) * | 2011-04-26 | 2011-10-05 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒ns1蛋白特异性b细胞抗原表位多肽及其应用 |
CN105085684A (zh) * | 2014-05-14 | 2015-11-25 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
CN108883166A (zh) * | 2016-03-25 | 2018-11-23 | 国立大学法人大阪大学 | 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗 |
CN109475593A (zh) * | 2016-06-24 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于治疗心血管疾病的组合物和方法 |
CN110072876A (zh) * | 2016-12-09 | 2019-07-30 | 深圳华大生命科学研究院 | 多肽及其应用 |
CN109897110A (zh) * | 2017-12-08 | 2019-06-18 | 深圳华大生命科学研究院 | 纳米抗体及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨建岭: "免疫干预新策略的研究进展及展望", 中国科学基金 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022021000A1 (zh) | 2022-02-03 |
CN114981288B (zh) | 2024-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210284721A1 (en) | Modified antibody compositions, methods of making and using thereof | |
US20230331822A1 (en) | SARS-COV-2 spike protein binding molecule and application thereof | |
KR102257462B1 (ko) | 항-pcsk9 단일클론 항체 | |
US11186630B2 (en) | Anti-transthyretin human antibody | |
RU2764740C1 (ru) | Биспецифическое антитело против вируса бешенства и его применение | |
US20040258699A1 (en) | Immunotherapeutics for biodefense | |
KR20230118922A (ko) | 항lag-3의 단일 클론 항체, 이의 항원 결합 단편 및이의 응용 | |
US20230091895A1 (en) | Nanobody for pcsk9 and application thereof | |
WO2020208150A1 (en) | Protein binders for irhom2 | |
CN111171148A (zh) | 一种抗补体c3分子的人源化单链抗体及其应用 | |
EP2464657B1 (en) | Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity | |
CN110872353B (zh) | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 | |
CN114981288B (zh) | 一种抗体结合的特征性表位及其应用 | |
CN114195888B (zh) | 一种抗新冠抗体药物的核心序列 | |
CN115960238A (zh) | 一种能特异性结合pcsk9抗原的纳米抗体及其制备方法 | |
CN107074925A (zh) | 用于预防和/或治疗亨廷顿氏病的物质和方法 | |
CN113234152B (zh) | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 | |
CN114349861A (zh) | 一种抗pd1纳米抗体及其制备方法和应用 | |
EP4153313A1 (en) | Anti-sars-cov-2 antibodies and uses thereof | |
US20240228603A1 (en) | Modified antibody compositions, methods of making and using thereof | |
Ballman et al. | Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety | |
CN115124616A (zh) | 特异性针对SARS-CoV-2 RBD的纳米抗体 | |
CN117659191A (zh) | 一种抗cd9单域抗体及其应用 | |
CN116333139A (zh) | 一种抗fda0128抗体、其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |